Photo from wikipedia
In this issue of Blood, Roeker et al report an updated analysis of an international, multicenter study on the outcomes of 374 patients with chronic lymphocytic leukemia (CLL) diagnosed with… Click to show full abstract
In this issue of Blood, Roeker et al report an updated analysis of an international, multicenter study on the outcomes of 374 patients with chronic lymphocytic leukemia (CLL) diagnosed with COVID-19. The current analysis evaluated the case fatality rate in an expanded cohort with a longer followup period and compared outcomes over time. They found that overall case fatality rate remained high (28%). However, it appeared to have dropped from 35% in an early cohort, diagnosed before May 2020, to 11% in a later cohort, diagnosed after May 2020. Interestingly, an overall survival benefit was observed in patients treated with remdesivir and convalescent plasma.
Journal Title: Blood
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!